Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy

Archives of Dermatology

Volumn 141, Issue 6, 2005, Pages 705-710

  Powell, Ann Marie ^a   Sakuma Oyama, Yohko ^a   Oyama, Noritaka ^a   Albert, Sandra ^a   Bhogal, Balbir ^a   Kaneko, Fumio ^b   Nishikawa, Takeji ^c   Black, Martin M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b FUKUSHIMA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN BP 180; UNCLASSIFIED DRUG; AUTOANTIGEN; BP180 AUTOANTIGEN; DIAGNOSTIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PEMPHIGOID; PEMPHIGOID GESTATIONIS; POLYMORPHIC URTICARIAL PAPULES AND PLAQUES OF PREGNANCY; PREGNANCY DISORDER; PRIORITY JOURNAL; PRURITUS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; BLOOD; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; EVALUATION; GESTATIONAL AGE; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; METHODOLOGY; NEEDLE BIOPSY; PREGNANCY; PREGNANCY COMPLICATION; PROBABILITY; RISK ASSESSMENT; SEROLOGY; URTICARIA;

ADULT; AUTOANTIGENS; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; IMMUNOHISTOCHEMISTRY; PEMPHIGOID, BULLOUS; PREGNANCY; PREGNANCY COMPLICATIONS; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, VESICULOBULLOUS; URTICARIA;

EID: 21844449949     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.6.705     Document Type: Article

References (41)

1. Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol. 1999;24:255-259.
2. Shornick JK, Bangert JL, Freeman RG, Gilliam JN. Herpes gestationis: clinical and histological features of twenty eight cases. J Am Acad Dermatol. 1983;8:214-224.
3. Hodge L, Black MM, Ramnarain N, Bhogal B. Indirect complement immunofluorescence in the immunopathological assessment of bullous pemphigoid, cicatricial pemphigoid and herpes gestationis. Clin Exp Dermatol. 1978;3:61-67.
4. Katz SI, Hertz KC, Yaoita H. Herpes gestationis: immunopathology and characterization of the HG factor. J Clin Invest. 1976;57:1434-1441.
5. Morrison LH, Labib RS, Zone JJ, Anhalt GJ. Herpes gestationis antibodies recognize a 180-kD human epidermal antigen. J Clin Invest. 1988;81:2023-2026.
6. Jenkins RE, Shornick J. Pemphigoid (herpes) gestationis. In: Black M, McKay M, eds. Obstetric and Gynaecologic Dermatology. 2nd ed. London, England: Mosby International Ltd; 2002:29-37.
7. Lawley TJ, Stingl G, Katz SI. Fetal and maternal risk factors in herpes gestationis. Arch Dermatol. 1978;114:552-555.
8. Holmes RC, Black MM. The fetal prognosis in pemphigoid gestationis (herpes gestationis). Br J Dermatol. 1984;110:67-72.
9. Kelly SE, Fleming S, Bhogal BS, Wojnarowska F, Black MM. Immunopathology of the placenta in pemphigoid gestationis and linear IgA disease. Br J Dermatol. 1989;120:735-743.
10. Mascaro JM Jr, Lecha M, Mascaro JM. Fetal morbidity in herpes gestationis. Arch Dermatol. 1995;131:1209-1210.
11. Shornick JK. Herpes gestationis. J Am Acad Dermatol. 1987;17:539-556.
12. Bhogal BS, Black MM. Diagnosis, diagnostic and research techniques. In: Wojnorowska F, Briggaman RA, eds. Management of Blistering Diseases. 1st ed. London, England: Chapman & Hall Ltd; 1990:15-34.
13. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common noncollagenous site on the BP180 ectodomain. J Immunol. 1993;151:5742-5750.
14. Matsumura K, Amagai M, Nishikawa T, Hashimoto T. The majority of bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain of the 180-kDa bullous pemphigoid antigen. Arch Dermatol Res. 1996;288:507-509.
15. Murakami H, Amagai M, Higashiyama M, et al. Analysis of antigens recognized by autoantibodies in herpes gestationis: usefulness of immunoblotting using a fusion protein representing an extracellular domain of the 180kD bullous pemphigoid antigen. J Dermatol Sci. 1996;13:112-117.
16. Lin MS, Gharia M, Fu CL, et al. Molecular mapping of the major epitopes of BP180 recognized by herpes gestationis autoantibodies. Clin Immunol. 1999;92:285-292.
17. Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol. 1994;102:878-881.
18. Lin MS, Gharia MA, Swartz SJ, Diaz LA, Giudice GJ. Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol. 1999;162:4991-4997.
19. Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002;119:1065-1073.
20. Lin MS, Fu CL, Giudice GJ, et al. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol. 2000;115:955-961.
21. Balding SD, Prost C, Diaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol. 1996;106:141-146.
22. Kromminga A, Scheckenbach C, Georgi M, et al. Patients with bullous pemphigoid and linear IgA disease show dual IgA and IgG autoimmune response to BP180. J Autoimmun. 2000;15:293-300.
23. Lin MS, Fu CL, Olague-Marchan M, et al. Autoimmune responses in patients with linear IgA bullous dermatoses: both autoantibodies and T-lymphocytes recognize the NC16a domain of the BP180 molecule. Clin Immunol. 2002;102:310-319.
24. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480-2488.
25. Liu Z, Diaz LA, Swartz SJ, et al. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol. 1995;155:5449-5454.
26. Yamamoto K, Inoue N, Masuda R, et al. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol. 2002;118:485-492.
27. Schmidt E, Reimer S, Kruse N, et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured keratinocytes. J Invest Dermatol. 2000;115:842-848.
28. Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol. 2002;118:664-671.
29. Schmidt E, Kromminga A, Mimietz S, et al. A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. J Autoimmun. 2002;18:299-303.
30. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16a and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol. 1998;139:365-370.
31. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109:679-683.
32. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002;30:224-232.
33. Haase C, Büdinger L, Borradori L, et al. Detection of IgG autoantibodies in the sera of patients with bullous pemphigoid and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen-2. J Invest Dermatol. 1998;110:282-286.
34. Sitaru C, Powell J, Messer G, Brocker EB, Wojnarowska F, Zillikens D. Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol. 2004;103:757-763.
35. Chorzelski TP, von Weiss JF, Lever WF. Clinical significance of autoantibodies in pemphigus. Arch Dermatol. 1966;93:570-576.
36. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144:775-780.
37. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26:585-589.
38. Pas HH, de Jong MC, Jonkman MF, Heeres K, Slijper-Pal IJ, van der Meer JB. Bullous pemphigoid: serum antibody titre and antigen specificity. Exp Dermatol. 1995;4:372-376.
39. Ghohestani RF, Cozzani E, Kanitakis J, Nicolas JF, Faure M, Claudy AL. BPAg2 antibodies are present at lower levels than BPAg1 antibodies in serum from patients with bullous pemphigoid. Eur J Dermatol. 1996;6:491-494.
40. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174-178.
41. Amo Y, Ohkawa T, Tatsuta M, et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2001;26:14-18.